Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?

Current Hematologic Malignancy Reports

Volumn 10, Issue 3, 2015, Pages 282-291

  Bejar, Rafael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clonal cytopenias; Cytopenic patients; Myelodysplastic syndrome; Somatic mutations

Indexed keywords

BLOOD CELL COUNT; BONE MARROW EXAMINATION; CHROMOSOME ABERRATION; CYTOPENIA; DYSPLASIA; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GERMLINE MUTATION; HUMAN; MOLECULAR DIAGNOSIS; MYELODYSPLASTIC SYNDROME; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; BONE MARROW; DNA SEQUENCE; GENETICS; METABOLISM; MUTATION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY;

BONE MARROW; CHROMOSOME ABERRATIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYELODYSPLASTIC SYNDROMES; SEQUENCE ANALYSIS, DNA;

EID: 84941745959     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-015-0270-5     Document Type: Review

References (66)

1. Liesveld JL, Lichtman MA. Myelodysplastic syndromes. In: Kaushansky K, Lichtman MA, Seligsohn U, et al., editors. Williams hematology. Eighthth ed. New York: McGraw-Hill Medical; 2010. p. 1249–76.
2. Font P, Loscertales J, Soto C, et al. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. Ann Hematol. 2015;94:565–73.
3. Font P, Loscertales J, Benavente C, et al. Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol. 2013;92:19–24.
4. Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014;99:956–64.
5. Greenberg PL, Stone RM, Bejar R, et al. Myelodysplastic syndromes, version 2.2015. J Natl Compr Cancer Netw: JNCCN. 2015;13:261–72.
6. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64.
7. Valent P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematol / Edu Program Am Soc Hematol Am Soc Hematol Edu Program. 2012;2012:485–91.
8. Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2014;20:161.
9. DePalma L, Delgado P, Werner M. Diagnostic discrimination and cost effective assay strategy for leukocyte alkaline phosphatase. Clin Chim Acta. 1996;244:83–90.
10. Neumann F, Herold C, Hildebrandt B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol. 2003;70:1–10.
11. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.
12. Pemmaraju N, Moliterno AR. From Philadelphia-negative to JAK2-positive: effect of genetic discovery on risk stratification and management. Am Soc Clin Oncol Educ Book. 2015;35:139–45.
13. Lindsley RC, Ebert BL. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013;8:21–47. Excellent review on somatic mutations and the molecular pathology of MDS.
14. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506. This is one of three large studies to demonstrate that somatic mutations have prognostic significance independent of the IPSS.
15. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27. This is one of three large studies that examined patterns of mutations and their prognostic value in a large cohort of MDS patients.
16. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leuk: Off J Leuk Soc Am, Leuk Res Fund, UK. 2014;28:241–7. This is one of three large studies that examined patterns of mutations and their prognostic value in a large cohort of MDS patients.
17. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147–52.
18. Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28:78–87.
19. Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol: Off J Am Soc Clin Oncol. 2014;32:2691–8. This article demonstrates the predictive value of somatic mutations in MDS patients undergoing allogeneic stem cell transplant.
20. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705–12. This article demonstrates the predictive value of somatic mutations in MDS patients treated with hypomethylating agents.
21. Gondek LP, DeZern AE. I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep. 2014;9:389–99.
22. Kohlmann A, Bacher U, Schnittger S, et al. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Leuk Lymphoma. 2014;55:1725–34.
23. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007;31:727–36.
24. Komrokji RS, Corrales-Yepez M, Al Ali N, et al. Validation of the MD Anderson prognostic risk model for patients with myelodysplastic syndrome. Cancer. 2012;118:2659–64.
25. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538–43.
26. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:3376–82.
27. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183–6.
28. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.
29. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124:2698–704.
30. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366:95–6.
31. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–9. This article describes somatic mutations in 8 splicing factor genes and their frequency in myeloid malignancies.
32. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4:1088–101.
33. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365:2497–506.
34. Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood. 1996;88:59–65.
35. Busque L, Paquette Y, Provost S, et al. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood. 2009;113:3472–4.
36. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179–81.
37. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44:651–8.
38. Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44:642–50.
39. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98. This is one of two whole exome sequencing studies that describe age-related somatic mutations in the blood of GWAS participants.
40. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.
41. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87. This is one of two whole exome sequencing studies that describe age-related somatic mutations in the blood of GWAS participants.
42. Steensma DP, Bejar R, Jaiswal S, et al.: Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 2015. Timely perspective article describing the implications of CHIP and CCUS on the use of somatic mutations for the diagnosis of MDS.
43. Steensma DP. Dysplasia has a differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep. 2012;7:310–20. An excellent guide to the challenges associated with the diagnosis of MDS.
44. Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res. 2012;36:1–5.
45. Schroeder T, Ruf L, Bernhardt A, et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol. 2010;21:2267–71.
46. Hall J, Al Hafidh J, Balmert E, et al. Somatic mutations indicative of clonal hematopoiesis are present in a large fraction of cytopenic patients who lack diagnostic evidence of MDS. Blood. 2014;124:3272.
47. Kwok B, Reddy P, Lin K, et al. Next-generation sequencing (NGS)-based profiling of idiopathic cytopenia of undetermined significance (ICUS) identifies a subset of patients with genomic similarities to lower-risk myelodysplastic syndrome (MDS). Blood. 2014;124:166.
48. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–15.
49. Andersson EI, Rajala HL, Eldfors S, et al. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J. 2013;3:e168.
50. Rajala HL, Eldfors S, Kuusanmaki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121:4541–50.
51. Genovese G, Jaiswal S, Ebert BL, et al. Clonal hematopoiesis and blood-cancer risk. N Engl J Med. 2015;372:1071–2.
52. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.
53. Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658–70.
54. Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180–5.
55. West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci. 2014;1310:111–8.
56. Talwalkar SS, Yin CC, Naeem RC, et al. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med. 2010;134:1010–5.
57. Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA. 2011;305:1568–76.
58. Zatterale A, Calzone R, Renda S, et al. Identification and treatment of late onset Fanconi’s anemia. Haematologica. 1995;80:535–8.
59. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65.
60. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.
61. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia. 2012;26:1137–40.
62. Juneja SK, Imbert M, Sigaux F, et al. Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol. 1983;36:566–9.
63. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;26:2014–03.
64. Malcovati L, Karimi M, Papaemmanuil E, et al.: SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 2015. This study demonstrates how somatic mutations inSF3B1identify a molecular subtype of MDS with share clinical features.
65. Volkert S, Kohlmann A, Schnittger S, et al. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes, Chromosomes Cancer. 2014;3:22151.
66. Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes, Chromosomes Cancer. 2012;51:1086–92.